dc.contributor.author | Harding, D | |
dc.contributor.author | Giles, SL | |
dc.contributor.author | Brown, MRD | |
dc.contributor.author | Ter Haar, GR | |
dc.contributor.author | van den Bosch, M | |
dc.contributor.author | Bartels, LW | |
dc.contributor.author | Kim, Y-S | |
dc.contributor.author | Deppe, M | |
dc.contributor.author | deSouza, NM | |
dc.date.accessioned | 2018-01-11T14:27:27Z | |
dc.date.issued | 2018-04-01 | |
dc.identifier.citation | Clinical oncology (Royal College of Radiologists (Great Britain)), 2018, 30 (4), pp. 233 - 242 | |
dc.identifier.issn | 0936-6555 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/992 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.doi | 10.1016/j.clon.2017.12.023 | |
dc.description.abstract | AIMS: To determine quality of life (QoL) outcomes after palliation of pain from bone metastases using magnetic resonance-guided high intensity focused ultrasound (MR-guided HIFU), measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL and the QLQ-BM22 questionnaires. MATERIALS AND METHODS: Twenty patients undergoing MR-guided HIFU in an international multicentre trial self-completed the QLQ-C15-PAL and QLQ-BM22 questionnaires before and on days 7, 14, 30, 60 and 90 post-treatment. Descriptive statistics were used to represent changes in symptom and functional scales over time and to determine their clinical significance. QoL changes were compared in pain responders and non-responders (who were classified according to change in worst pain score and analgesic intake, between baseline and day 30). RESULTS: Eighteen patients had analysable QoL data. Clinically significant improvements were seen in the QoL scales of physical functioning, fatigue, appetite loss, nausea and vomiting, constipation and pain in the 53% of patients who were classified as responders at day 30. No significant changes were seen in the 47% of patients who were non-responders at this time point. CONCLUSION: Local treatment of pain from bone metastases with MR-guided HIFU, even in the presence of disseminated malignancy, has a substantial positive effect on physical functioning, and improves other symptomatic QoL measures. This indicated a greater response to treatment over and above pain control alone. MR-guided HIFU is non-invasive and should be considered for patients with localised metastatic bone pain and poor QoL. | |
dc.format | Print-Electronic | |
dc.format.extent | 233 - 242 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE LONDON | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Bone Neoplasms | |
dc.subject | Palliative Care | |
dc.subject | Ultrasonic Therapy | |
dc.subject | Quality of Life | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Surveys and Questionnaires | |
dc.subject | Cancer Pain | |
dc.title | Evaluation of Quality of Life Outcomes Following Palliative Treatment of Bone Metastases with Magnetic Resonance-guided High Intensity Focused Ultrasound: An International Multicentre Study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-11-29 | |
rioxxterms.versionofrecord | 10.1016/j.clon.2017.12.023 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical oncology (Royal College of Radiologists (Great Britain)) | |
pubs.issue | 4 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Therapeutic Ultrasound | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Therapeutic Ultrasound | |
pubs.publication-status | Published | |
pubs.volume | 30 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Magnetic Resonance | |
icr.researchteam | Therapeutic Ultrasound | |
dc.contributor.icrauthor | Ter Haar, Gail | |
dc.contributor.icrauthor | deSouza, Nandita | |